Managed Care Calendar
- AAPM 2010 Clinical Meeting
Poll
Trends in Medicare and Medicaid Managed Care: Implications for the Future

Medicare and Medicaid benchmarking data, when compared
between years, help medical directors, pharmacists,
and other practitioners foresee changes in these
programs. Tracking patterns of utilization, cost, and strategy is
especially significant now, with health care reform at the center
of political debate and with many Americans facing unemployment
and economic uncertainty.
As this document goes to press, the sanofi-aventis Public Payer
Digest is in production; it will be released in November. The
Public Payer Digest combines data that appeared in two predecessors
in the Managed Care Digest Series®—the Government Digest
and the Senior Care Digest1—and provides a comprehensive
overviewof theMedicare andMedicaid programs and of key elements
of senior care in a single publication.
POTENTIAL IMPACT OF HEALTH CARE REFORM
It is nearly impossible to discuss any aspect of care without
considering the potential effects of the economy and
health care reform. During a July 22, 2009, press conference,
President Barack Obama talked about requiring Congress to
vote on recommendations by the Medicare Payment
Advisory Commission (MEDPAC) to incentivize and
empower important changes. He stressed that the recommendations
would not change benefits but instead would
change how benefits are delivered. Nonetheless, it is still
unclear what shape reform will take or even how a public
option might look.
Darlene M. Mednick, RPh, MBA, PhD, FAMCP, senior vice
president of Strategic Business Development, Managed
Markets, at CareMed Pharmaceutical Services, notes, “There
are different health care reform components on the table.
The government may gravitate toward initiatives modeled
after those that already have been implemented—such as a
Part D−like benefit.”
According to Dan Mendelson, president of Avalere Health,
“What’s being proposed for health care reform sounds great,
but the question remains how we will do it. It’s too early to tell
what coverage might look like in a public option.” However,
he says, “Controlling costs often involves saying no, and we
haven’t seen the government do much of that to date.”
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.







